Tada, hopefully you are correct in your assessment of Apabetalone. A lot of outside research would certainly support the idea that Apabetalone is potentially very valuable. I totally agree that a sale of RVX would be a great thing if it were to get its development into the hands of competent management that could set and hit timely business targets. Hopefully Eversana is providing some of the answer to fill the leadership void at RVX. I remember Don telling me at the AGM after the BoM readout that management felt the EV of RVX was about $4B USD and further saying that selling it at that price would also be "very nice for Zenith".

Since that time there has been nothing but more positive scientific validation for Apabetalone and one would think by extension increasing the value of the company. I for one would be a very happy shareholder if I woke up one morning soon to find that the company had been sold for $4B. I would also be happy that my investment in Zenith would finally be properly funded. 

Would be nice if Don was for once correct and that $4B USD was a realistic number that he could convert into a sale price.  As I said I would be happy to take the money and run.